Live Breaking News & Updates on Postmenopausal vulvovaginal atrophy

Stay informed with the latest breaking news from Postmenopausal vulvovaginal atrophy on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Postmenopausal vulvovaginal atrophy and stay connected to the pulse of your community

Lupin, Endoceutics focus on women's health in Canada

Lupin, Endoceutics focus on women's health in Canada
Lupin, Endoceutics focus on women's health in Canada
09 March 2021 | News
Source credit: Shutterstock
Lupin Pharma, a subsidiary of global pharma major Lupin Ltd, has announced a partnership with Endoceutics, a women’s health focused innovative Canadian biotech company, to commercialise Intrarosa® in Canada.
Intrarosa® is Endoceutic’s flagship product indicated for the treatment of postmenopausal vulvovaginal atrophy offered as a vaginal ovule containing 6.5 mg of Prasterone.
Commenting on the partnership, Dr Sofia Mumtaz, President, Lupin Pharma Canada said, “We are very pleased to partner with Endoceutics to bring this long-awaited innovative product to the Canadian market. Intrarosa will not only expand and strengthen our product portfolio into women’s health in Canada but will cater to satisfy the unmet medical needs.”

Canada , Canadian , Dennis-turpin , Lupin-ltd , Lupin-pharma , Lupin-pharma-canada , Chief-executive-officer , Lupin , Endoceutics , Intrarosa , Postmenopausal-vulvovaginal-atrophy , Vaginal-ovule